Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages

Jun Yu, Amanda L. Blackford, Marco Dal Molin, Christopher Wolfgang, Michael S Goggins

Research output: Contribution to journalArticle

Abstract

Objective: Although pancreatic ductal adenocarcinoma is considered a rapidly progressive disease, mathematical models estimate that it takes many years for an initiating pancreatic cancer cell to grow into an advanced stage cancer. In order to estimate the time it takes for a pancreatic cancer to progress through different tumor, node, metastasis (TNM) stages, we compared the mean age of patients with pancreatic cancers of different sizes and stages. Design: Patient age, tumour size, stage and demographic information were analysed for 13 131 patients with pancreatic ductal adenocarcinoma entered into the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database. Multiple linear regression models for age were generated, adjusting for patient ethnicity, gender, tumour location and neoplastic grades. Results: African-American ethnicity and male gender were associated with an earlier age at diagnosis. Patients with stage I cancers (mean age 64.8 years) were on average 1.3 adjusted years younger at diagnosis than those with stage IV cancers (p=0.001). Among patients without distant metastases, those with T1 stage cancers were on average 1.06 and 1.19 adjusted years younger, respectively, than patients with T3 or T4 cancers (p=0.03 for both). Among patients with stage IIB cancers, those with T1/T2 cancers were 0.79 adjusted years younger than those with T3 cancers (p=0.06). There was no significant difference in the mean adjusted age of patients with stage IA versus stage IB cancers. Conclusions: These results are consistent with the hypothesis that once pancreatic ductal adenocarcinomas become detectable clinically progression from low-stage to advanced-stage disease is rapid.

Original languageEnglish (US)
Pages (from-to)1783-1789
Number of pages7
JournalGut
Volume64
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Adenocarcinoma
Neoplasms
Pancreatic Neoplasms
Linear Models
Neoplasm Metastasis
National Cancer Institute (U.S.)
African Americans
Epidemiology
Theoretical Models
Demography
Databases

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. / Yu, Jun; Blackford, Amanda L.; Dal Molin, Marco; Wolfgang, Christopher; Goggins, Michael S.

In: Gut, Vol. 64, No. 11, 01.11.2015, p. 1783-1789.

Research output: Contribution to journalArticle

@article{d1f05516db794479a4177c839402c928,
title = "Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages",
abstract = "Objective: Although pancreatic ductal adenocarcinoma is considered a rapidly progressive disease, mathematical models estimate that it takes many years for an initiating pancreatic cancer cell to grow into an advanced stage cancer. In order to estimate the time it takes for a pancreatic cancer to progress through different tumor, node, metastasis (TNM) stages, we compared the mean age of patients with pancreatic cancers of different sizes and stages. Design: Patient age, tumour size, stage and demographic information were analysed for 13 131 patients with pancreatic ductal adenocarcinoma entered into the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database. Multiple linear regression models for age were generated, adjusting for patient ethnicity, gender, tumour location and neoplastic grades. Results: African-American ethnicity and male gender were associated with an earlier age at diagnosis. Patients with stage I cancers (mean age 64.8 years) were on average 1.3 adjusted years younger at diagnosis than those with stage IV cancers (p=0.001). Among patients without distant metastases, those with T1 stage cancers were on average 1.06 and 1.19 adjusted years younger, respectively, than patients with T3 or T4 cancers (p=0.03 for both). Among patients with stage IIB cancers, those with T1/T2 cancers were 0.79 adjusted years younger than those with T3 cancers (p=0.06). There was no significant difference in the mean adjusted age of patients with stage IA versus stage IB cancers. Conclusions: These results are consistent with the hypothesis that once pancreatic ductal adenocarcinomas become detectable clinically progression from low-stage to advanced-stage disease is rapid.",
author = "Jun Yu and Blackford, {Amanda L.} and {Dal Molin}, Marco and Christopher Wolfgang and Goggins, {Michael S}",
year = "2015",
month = "11",
day = "1",
doi = "10.1136/gutjnl-2014-308653",
language = "English (US)",
volume = "64",
pages = "1783--1789",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages

AU - Yu, Jun

AU - Blackford, Amanda L.

AU - Dal Molin, Marco

AU - Wolfgang, Christopher

AU - Goggins, Michael S

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Objective: Although pancreatic ductal adenocarcinoma is considered a rapidly progressive disease, mathematical models estimate that it takes many years for an initiating pancreatic cancer cell to grow into an advanced stage cancer. In order to estimate the time it takes for a pancreatic cancer to progress through different tumor, node, metastasis (TNM) stages, we compared the mean age of patients with pancreatic cancers of different sizes and stages. Design: Patient age, tumour size, stage and demographic information were analysed for 13 131 patients with pancreatic ductal adenocarcinoma entered into the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database. Multiple linear regression models for age were generated, adjusting for patient ethnicity, gender, tumour location and neoplastic grades. Results: African-American ethnicity and male gender were associated with an earlier age at diagnosis. Patients with stage I cancers (mean age 64.8 years) were on average 1.3 adjusted years younger at diagnosis than those with stage IV cancers (p=0.001). Among patients without distant metastases, those with T1 stage cancers were on average 1.06 and 1.19 adjusted years younger, respectively, than patients with T3 or T4 cancers (p=0.03 for both). Among patients with stage IIB cancers, those with T1/T2 cancers were 0.79 adjusted years younger than those with T3 cancers (p=0.06). There was no significant difference in the mean adjusted age of patients with stage IA versus stage IB cancers. Conclusions: These results are consistent with the hypothesis that once pancreatic ductal adenocarcinomas become detectable clinically progression from low-stage to advanced-stage disease is rapid.

AB - Objective: Although pancreatic ductal adenocarcinoma is considered a rapidly progressive disease, mathematical models estimate that it takes many years for an initiating pancreatic cancer cell to grow into an advanced stage cancer. In order to estimate the time it takes for a pancreatic cancer to progress through different tumor, node, metastasis (TNM) stages, we compared the mean age of patients with pancreatic cancers of different sizes and stages. Design: Patient age, tumour size, stage and demographic information were analysed for 13 131 patients with pancreatic ductal adenocarcinoma entered into the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) database. Multiple linear regression models for age were generated, adjusting for patient ethnicity, gender, tumour location and neoplastic grades. Results: African-American ethnicity and male gender were associated with an earlier age at diagnosis. Patients with stage I cancers (mean age 64.8 years) were on average 1.3 adjusted years younger at diagnosis than those with stage IV cancers (p=0.001). Among patients without distant metastases, those with T1 stage cancers were on average 1.06 and 1.19 adjusted years younger, respectively, than patients with T3 or T4 cancers (p=0.03 for both). Among patients with stage IIB cancers, those with T1/T2 cancers were 0.79 adjusted years younger than those with T3 cancers (p=0.06). There was no significant difference in the mean adjusted age of patients with stage IA versus stage IB cancers. Conclusions: These results are consistent with the hypothesis that once pancreatic ductal adenocarcinomas become detectable clinically progression from low-stage to advanced-stage disease is rapid.

UR - http://www.scopus.com/inward/record.url?scp=84947570345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947570345&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2014-308653

DO - 10.1136/gutjnl-2014-308653

M3 - Article

VL - 64

SP - 1783

EP - 1789

JO - Gut

JF - Gut

SN - 0017-5749

IS - 11

ER -